Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
IPO Date: October 31, 2008
Sector: Healthcare
Industry: Biotech
Market Cap: $614.65M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.12 | 3.33%
Avg Daily Range (30 D): $0.08 | 2.54%
Avg Daily Range (90 D): $0.08 | 2.40%
Institutional Daily Volume
Avg Daily Volume: 1.17M
Avg Daily Volume (30 D): .94M
Avg Daily Volume (90 D): .81M
Trade Size
Avg Trade Size (Sh.): 220
Avg Trade Size (Sh.) (30 D): 116
Avg Trade Size (Sh.) (90 D): 114
Institutional Trades
Total Inst.Trades: 220
Avg Inst. Trade: $1.71M
Avg Inst. Trade (30 D): $.96M
Avg Inst. Trade (90 D): $.98M
Avg Inst. Trade Volume: .5M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.27M
Avg Closing Trade (30 D): $1.09M
Avg Closing Trade (90 D): $1.09M
Avg Closing Volume: 639.48K
       
News
Feb 20, 2025 @ 8:22 AM
Will Moderna Stock Drop to $25? 1 Wall Street Anal...
Source: Eric Volkman
Jun 13, 2024 @ 9:12 AM
Ultragenyx (RARE) Moves 7.8% Higher: Will This Str...
Source: Zacks Equity Research
Jun 6, 2024 @ 3:15 PM
Treatment with Arbutus’ Imdusiran and VTP-3...
Source: Arbutus Biopharma Corporation
Jun 5, 2024 @ 6:30 AM
Arbutus’ Imdusiran with Short Course Interf...
Source: Arbutus Biopharma Corporation
May 29, 2024 @ 11:30 AM
Arbutus to Participate in Jefferies Global Healthc...
Source: Arbutus Biopharma Corporation
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-.38 $-.07 $-.38
Diluted EPS $-.38 $-.07 $-.38
Revenue $ 6.17M $ 1.57M $ 6.17M
Gross Profit $ $ $
Net Income / Loss $ -69.92M $ -12.53M $ -69.92M
Operating Income / Loss $ -76.32M $ -13.93M $ -76.32M
Cost of Revenue $ $ $
Net Cash Flow $ 10.05M $ 4.48M $ 10.05M
PE Ratio    
Splits
Nov 04, 2010:   5:1